| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding | |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | Entrez:930 MIM:107265 HGNC:HGNC:1633 Ensembl:ENSG00000177455 AllianceGenome:HGNC:1633 | |
| Description | CD19 molecule | |||||
| GTO ID | GTC2071 |
| Trial ID | NCT03876769 |
| Disease | B-Cell Acute Lymphoblastic Leukemia |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | Kymriah|Tisagenlecleucel |
| Generation | 2nd |
| Phase | Phase2 |
| Recruitment status | Recruiting |
| Title | Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients |
| Year | 2019 |
| Country | United States |
| Company sponsor | Novartis Pharmaceuticals |
| Other ID(s) | CCTL019G2201J|2017-002116-14 |
| Vector information | |||||
|
|||||
| Cohort 1 | |||||||||||||
|
|||||||||||||